Overview
- Adam Rehman, 13, was among the first UK children to receive Casgevy (exa-cel) for beta-thalassaemia, according to NHS Blood and Transplant.
- He revisited Royal Manchester Children’s Hospital to thank therapeutic apheresis nurse Clair Baron for her role in his care.
- Treated in November 2024, he has returned to school and resumed activities after years of monthly blood transfusions from infancy.
- The one-time ex vivo procedure edits a patient’s stem cells with the Crispr tool and reinfuses them to trigger healthy red blood cell production.
- Casgevy carries a £1.65 million list price per patient, with a confidential NHS–Vertex agreement indicating the health service pays less.